397 related articles for article (PubMed ID: 17617302)
21. Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms.
Gad GF; El-Domany RA; Zaki S; Ashour HM
J Antimicrob Chemother; 2007 Nov; 60(5):1010-7. PubMed ID: 17906321
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries.
Castanheira M; Deshpande LM; Costello A; Davies TA; Jones RN
J Antimicrob Chemother; 2014 Jul; 69(7):1804-14. PubMed ID: 24603963
[TBL] [Abstract][Full Text] [Related]
23. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
Sakyo S; Tomita H; Tanimoto K; Fujimoto S; Ike Y
J Antibiot (Tokyo); 2006 Apr; 59(4):220-8. PubMed ID: 16830889
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
Mohanty S; Maurya V; Gaind R; Deb M
J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
[TBL] [Abstract][Full Text] [Related]
25. Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates.
Naenna P; Noisumdaeng P; Pongpech P; Tribuddharat C
Southeast Asian J Trop Med Public Health; 2010 May; 41(3):614-24. PubMed ID: 20578550
[TBL] [Abstract][Full Text] [Related]
26. [Carbapenem resistance determined by metalloenzymes in clinical isolates of Pseudomonas aeruginosa].
Sánchez A; Salso S; Culebras E; Picazo JJ
Rev Esp Quimioter; 2004 Dec; 17(4):336-40. PubMed ID: 15696224
[TBL] [Abstract][Full Text] [Related]
27. Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan.
Nadkarni AS; Schliep T; Khan L; Zeana CB
Am J Infect Control; 2009 Mar; 37(2):121-6. PubMed ID: 19249638
[TBL] [Abstract][Full Text] [Related]
28. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem.
Farra A; Islam S; Strålfors A; Sörberg M; Wretlind B
Int J Antimicrob Agents; 2008 May; 31(5):427-33. PubMed ID: 18375104
[TBL] [Abstract][Full Text] [Related]
29. Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit.
Kohlenberg A; Weitzel-Kage D; van der Linden P; Sohr D; Vögeler S; Kola A; Halle E; Rüden H; Weist K
J Hosp Infect; 2010 Apr; 74(4):350-7. PubMed ID: 20170982
[TBL] [Abstract][Full Text] [Related]
30. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City.
Quale J; Bratu S; Landman D; Heddurshetti R
Clin Infect Dis; 2003 Jul; 37(2):214-20. PubMed ID: 12856214
[TBL] [Abstract][Full Text] [Related]
31. Dissemination of Pseudomonas aeruginosa producing SPM-1-like and IMP-1-like metallo-beta-lactamases in hospitals from southern Brazil.
Martins AF; Zavascki AP; Gaspareto PB; Barth AL
Infection; 2007 Dec; 35(6):457-60. PubMed ID: 18034208
[TBL] [Abstract][Full Text] [Related]
32. Beta-lactam resistance mechanisms in Pseudomonas aeruginosa strains causing bloodstream infections: comparative results between Brazilian and American isolates.
Fehlberg LC; Xavier DE; Peraro PP; Marra AR; Edmond MB; Gales AC
Microb Drug Resist; 2012 Aug; 18(4):402-7. PubMed ID: 22455540
[TBL] [Abstract][Full Text] [Related]
33. [Carbapenem resistance in Pseudomonas aeruginosa isolates: an example of interaction between different mechanisms].
Santella G; Pollini S; Docquier JD; Almuzara M; Gutkind G; Rossolini GM; Radice M
Rev Panam Salud Publica; 2011 Dec; 30(6):545-8. PubMed ID: 22358400
[TBL] [Abstract][Full Text] [Related]
34. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
[TBL] [Abstract][Full Text] [Related]
35. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia.
Tam VH; Chang KT; Schilling AN; LaRocco MT; Genty LO; Garey KW
Diagn Microbiol Infect Dis; 2009 Mar; 63(3):279-85. PubMed ID: 19135330
[TBL] [Abstract][Full Text] [Related]
36. ISPa46, a novel insertion sequence in the oprD porin gene of an imipenem-resistant Pseudomonas aeruginosa isolate from a cystic fibrosis patient in Marseille, France.
Diene SM; L'homme T; Bellulo S; Stremler N; Dubus JC; Mely L; Leroy S; Degand N; Rolain JM
Int J Antimicrob Agents; 2013 Sep; 42(3):268-71. PubMed ID: 23880169
[TBL] [Abstract][Full Text] [Related]
37. Molecular investigation of carbapenem resistance among multidrug-resistant Pseudomonas aeruginosa isolated clinically in Thailand.
Khuntayaporn P; Montakantikul P; Santanirand P; Kiratisin P; Chomnawang MT
Microbiol Immunol; 2013 Mar; 57(3):170-8. PubMed ID: 23278679
[TBL] [Abstract][Full Text] [Related]
38. Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa carrying metallo-beta-lactamase genes in Taiwan.
Huang YT; Chang SC; Lauderdale TL; Yang AJ; Wang JT
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):211-6. PubMed ID: 17521840
[TBL] [Abstract][Full Text] [Related]
39. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.
Tam VH; Chang KT; Abdelraouf K; Brioso CG; Ameka M; McCaskey LA; Weston JS; Caeiro JP; Garey KW
Antimicrob Agents Chemother; 2010 Mar; 54(3):1160-4. PubMed ID: 20086165
[TBL] [Abstract][Full Text] [Related]
40. Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study.
Llanes C; Pourcel C; Richardot C; Plésiat P; Fichant G; Cavallo JD; Mérens A;
J Antimicrob Chemother; 2013 Aug; 68(8):1763-71. PubMed ID: 23629014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
